This site is intended for healthcare professionals outside the U.S.
ESTEEM® 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 with nail psoriasis at baseline (NAPSI score ≥1; 558/844, 66.1%), who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52.
At week 16, mean percent improvement in NAPSI score was significantly greater with OTEZLA 30 mg BID (22.5%, n = 339) vs placebo (-6.5%, n = 178). P < 0.0001; full analysis set, LOCF.
ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; NAPSI, nail psoriasis severity index; PASI, Psoriasis Area and Severity Index.
Reference: 1. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). JAAD. 2015;74(1):134–142.
Please choose a country